Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.62 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 4/20 | 0.45 |
| ▸ | MC1R | Q01726 | 4/20 | 0.45 |
| ▸ | MC5R | P33032 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698088 | 0.91 | MC4R (0.60) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL4678742 | 0.89 | MC4R (0.58) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL6252350 | 0.89 | MC4R (0.58) | MC4RSMYD3MC3RMC1RMC5R | |
| Trifluoroacetic Acid SCHEMBL4698886 | 0.87 | MC4R (0.58) | MC4R | |
| SCHEMBL4697587 | 0.87 | MC4R (0.56) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL4698366 | 0.87 | MC4R (0.57) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL14559908 | 0.84 | MC4R (0.67) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL14591463 | 0.84 | MC4R (0.66) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL4698206 | 0.84 | MC4R (0.65) | MC4RSMYD3MC3RMC1RMC5R | |
| SCHEMBL14591290 | 0.84 | MC4R (0.57) | MC4RSMYD3MC3RMC1RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1440059-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | MC4R 1/4885SMYD3 2928/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.